Prospective Lifespan Cohort of Myocardial Infarction
China6,000 participantsStarted 2026-04-10
Plain-language summary
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.
The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.
The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Who can participate
Age range
18 Years – 74 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Age 18 to 74 years
Diagnosed with stable angina, unstable angina, or acute myocardial infarction
For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
Willing to participate and able to provide written informed consent
Able to complete baseline assessment, biospecimen collection, and long-term follow-up
Exclusion Criteria:
End-stage malignant tumor with expected survival of less than 1 year
Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C)
Active autoimmune disease or long-term use of immunosuppressive agents
Pregnant or breastfeeding women
Inability to provide informed consent or severe cognitive impairment
Previous participation in another clinical study that may conflict with this project
Any other condition considered by the investigators to make participation inappropriate
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is tracking all-cause mortality over what sounds like a long follow-up period — how long would I need to stay enrolled, and what does that kind of long-term commitment actually look like for me in terms of visits or check-ins?
2Since this trial isn't recruiting yet, what are my treatment options right now while I wait to see if enrollment opens, and would participating in this observational study affect any of those options?
3This cohort study covers people with acute MI, stable angina, and unstable angina — given my specific diagnosis, does my doctor think I'd be a meaningful fit for this kind of study, or would a different trial or standard care pathway make more sense for me first?
4Because this is listed as Phase NA, it sounds like it's an observational study rather than a treatment trial — can my doctor confirm that participating wouldn't change my actual medications or procedures, and that I'd still receive standard care throughout?
5Since the primary outcome being measured is all-cause mortality, what does my doctor think this study is trying to learn, and how might the findings eventually help people with my condition even if I don't see a direct personal benefit from joining?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Rate of all-cause mortality
Timeframe: From enrollment to the end of study follow-up, up to 5 years